Impact of oral bisphosphonate drug holiday on mortality following hip fracture: a population-based cohort study.
Miriam T Y LeungJustin P TurnerClara MarquinaJenni S IlomakiTim TranJ Simon BellPublished in: The Journal of clinical endocrinology and metabolism (2024)
Post-fracture mortality is higher in people who discontinue risedronate, but not alendronate, for 1 or 2 years after being adherent to treatment for at least 5 years. The type of bisphosphonate may be a factor to consider when planning drug holidays.